A phase II study of TAS-102 and Ramucirumab

A phase II study evaluating combination treatment of TAS-102 and Ramucirumab in patients with unresectable advanced or recurrent gastric cancer.

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCT2080224529

Enrollment

Registered

2019-01-28

Start date

2019-04-08

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Unresectable, advanced or recurrent

Interventions

investigational material(s) Generic name etc : Trifluridine/Tipiracil Hydrochloride INN of investigational material : Trifluridine/Tipiracil Hydrochloride Therapeutic category code : 422 Antimetabolic

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Has provided written informed consent 2. 20 years and over of age on the day of signing informed consent 3. Has histologically confirmed unresectable, advanced or recurrent gastric cancer 4. Is able to take medications orally 5. Is ECOG PS 0 or 1 6. Has negative pregnancy test 7. Has adequate organ function value 8. Is willing and able to comply with scheduled visits, treatment plans, laboratory tests, and other protocol procedures

Exclusion criteria

Exclusion criteria: 1. Had previously received TAS-102 2. Is pregnant or breast-feeding 3. Is inappropriate for enrolment into this study in the investigator's judgment

Design outcomes

Primary

Measure	Time frame
efficacy To evaluate efficacy of combination treatment of TAS-102 and Ramucirumab.	—

Secondary

Measure	Time frame
safety efficacy To evaluate other efficacy and safety of combination treatment of TAS-102 and Ramucirumab.	—

Countries

Japan

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026